Initiator Pharma (OM:INIT BTA) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

INIT BTA Stock Overview

A clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system.

About the company

INIT BTA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	5/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Earnings are forecast to grow 21.48% per year

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (DKK0)

Does not have a meaningful market cap (SEK350M)

Shareholders have been diluted in the past year

+ 1 more risk

Initiator Pharma A/S Competitors

Medivir

OM:MVIR

SEK 333.1m

Kancera

OM:KAN

SEK 239.0m

Mendus

OM:IMMU

SEK 413.4m

SynAct Pharma

OM:SYNACT

SEK 406.8m

Price History & Performance

Summary of all time highs, changes and price drops for Initiator Pharma
Historical stock prices
Current Share Price	SEK 7.20
52 Week High	SEK 8.20
52 Week Low	SEK 5.00
Beta	0.94
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	26.21%

Recent updates

Shareholder Returns

	INIT BTA	SE Biotechs	SE Market
7D	2.9%	1.3%	1.9%
1Y	n/a	30.1%	24.3%

Return vs Industry: Insufficient data to determine how INIT BTA performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how INIT BTA performed against the Swedish Market.

Price Volatility

Is INIT BTA's price volatile compared to industry and market?
INIT BTA volatility
INIT BTA Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.1%
Market Average Movement	5.6%
10% most volatile stocks in SE Market	11.7%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: INIT BTA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine INIT BTA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2016	2	Claus Olesen	www.initiatorpharma.com

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company’s pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression.

Initiator Pharma A/S Fundamentals Summary

How do Initiator Pharma's earnings and revenue compare to its market cap?
INIT BTA fundamental statistics
Market cap	SEK 350.33m
Earnings (TTM)	-SEK 48.24m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-7.3x

P/E Ratio

Is INIT BTA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INIT BTA income statement (TTM)
Revenue	DKK 0
Cost of Revenue	DKK 34.61m
Gross Profit	-DKK 34.61m
Other Expenses	-DKK 202.00k
Earnings	-DKK 34.41m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 26, 2022

Earnings per share (EPS)	-0.73
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	68.5%

How did INIT BTA perform over the long term?

See historical performance and comparison

Initiator Pharma OM:INIT BTA Stock Report